Online inquiry

IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2314MR)

This product GTTS-WQ2314MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Paroxysmal nocturnal hemoglobinuria (PNH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ2314MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1064MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-621
GTTS-WQ8946MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ11119MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MDX-060
GTTS-WQ9875MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ1991MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ6874MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DX-2930
GTTS-WQ7771MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GS-5745
GTTS-WQ7972MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GX-17
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW